Beyond Survival: The Architecture of Cancer Immunotherapies

As cancer treatments become more powerful and precise, the field of oncology is entering a new era. We are moving beyond the question of "Can we extend life?" to "How do we live with the biology these therapies unleash?"In this episode of Precision Signals, host Sean Khozin is joined by Dr. Afreen Shariff (Director of the Endocrine Neoplasia Program at Duke University) and Jon McDunn (President of Project DataSphere) to discuss the complexities of immune-related adverse events (irAEs). While immune checkpoint inhibitors have revolutionized outcomes for various cancers, they can also trigger inflammatory conditions affecting the thyroid, heart, and nervous system. Our guests explore the "double-edged sword" of immunotherapy and how data science, AI, and clinician-led innovation are bridging the gap between clinical trials and real-world patient care. In this episode, we discuss: The "Next HIV": Why Dr. Shariff believes cancer care is reaching a similar turning point in long-term management. The Gap in Data: Why traditional clinical trial reporting often fails to capture the nuances physicians see at the bedside. AI & Triage: How unique e-consult models and AI tools are helping oncologists manage complex side effects more efficiently. The Future of Oncology: Predictions on patient-driven care and the push for greater data accessibility to drive innovation.